

BioSpect

the business of Bio

24 years of leveraging the business of Bio
www.biospectrumindia.com

Boehringer Ingelheim India and NIPER Hajipur sign MoU to advance pharmaceutical research

24 April 2026 | News

A five-year partnership gives NIPER Hajipur researchers access to high-quality opnMeÂ® molecules



Boehringer Ingelheim India and the National Institute of Pharmaceutical Education and Research (NIPER), Hajipur have signed a Memorandum of Understanding (MoU) to advance pharmaceutical research, education and innovation.

The five-year collaboration will create new pathways for researchers and students in Bihar and the wider region to engage with global-standard open science platforms, joint research initiatives and capability-building programmes thus strengthening the talent pipeline for India's next phase of pharmaceutical innovation.

The MoU was signed at the Department of Pharmaceuticals in the presence of Manoj Joshi (IAS), Secretary, Department of Pharmaceuticals, Ministry of Chemicals and Fertilisers. Also present at the MoU signing ceremony was Dr Kinny Singh (IAS), Deputy Secretary, Department of Pharmaceuticals and Prof. K. Ruckmani, Director, NIPER Hajipur.

The MoU establishes a framework to strengthen academic and research collaboration in areas such as pharmaceutical technologies, novel drug delivery systems, joint research initiatives, academic exchange, and capability-building programmes.

As part of the MoU, Boehringer Ingelheim will enable NIPER Hajipur researchers and faculty to access opnMe®, its global open science portal.

Through opnMe®, scientists can access well-characterised pre-clinical tool compounds free of charge for their research. Boehringer Ingelheim has already shared more than 150 molecules with Indian institutions through opnMe®, and the collaboration with NIPER Hajipur extends this access to eastern India for the first time at this scale.

By strengthening the bridge between academic research and industry expertise, this partnership aims to contribute to the development of future-ready scientific talent and research pathways that can support more effective, accessible, and contribute, over time, to therapies that address the health needs of Indian patients and communities.